Ann Transl Med. 2019 Dec;7(23):717. doi: 10.21037/atm.2019.12.26.
Comparison of drugs facilitating endoscopy for patients with acute variceal bleeding: a systematic review and network meta-analysis.
Annals of translational medicine
Ziyuan Zou, Xinwen Yan, Huanpeng Lu, Xingshun Qi, Ye Gu, Xun Li, Bin Wu, Xiaolong Qi
Affiliations
Affiliations
- CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou 730000, China.
- The First School of Clinical Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
- Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Shenyang Military Area, Shenyang 110840, China.
- Department of Gastroenterology, The Sixth Peoples Hospital of Shenyang, Shenyang 110003, China.
- Department of Gastroenterology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China.
PMID: 32042733
PMCID: PMC6989971 DOI: 10.21037/atm.2019.12.26
Abstract
BACKGROUND: We aimed to compare the efficacy of different drugs facilitating endoscopy in patients with acute variceal bleeding.
METHODS: Databases were searched to identify randomized controlled trials which compared the efficacy of vasoactive drugs (vasopressin, terlipressin, octreotide, somatostatin) with placebo or each other. The primary outcomes were 6-week and 5-day mortality. Secondary outcomes were 5-day rebleeding, control of initial bleeding and adverse events. Pairwise and network meta-analysis were performed.
RESULTS: We identified 14 RCTs involved 2,187 patients. Four drugs had comparable clinical efficacy in all involving outcomes, except for adverse events. However, we do exhibit a superiority when vasopressin (OR, 4.40; 95% CI: 1.04-19.57), terlipressin (OR, 4.58; 95% CI: 1.63-13.63), octreotide (OR, 5.79; 95% CI: 2.41-16.71) and somatostatin (OR, 5.15; 95% CI: 1.40-27.39) were compared to placebo respectively as for initial hemostasis. In addition, only octreotide was more effective than placebo in decreasing 5-day rebleeding (OR, 0.44; 95% CI: 0.22-0.90). Meanwhile, octreotide was shown to have the highest probability ranking the best to improve initial hemostasis (mean rank =1.8) and carries a lowest risk of adverse events (9.1%) and serious adverse events (0.0%) compared to other drugs.
CONCLUSIONS: Balanced with curative effect and tolerability, octreotide may be the preferred vasoactive drug facilitating endoscopy.
2019 Annals of Translational Medicine. All rights reserved.
Keywords: Cirrhosis; endoscopy; hemorrhage; portal hypertension; vasoconstrictor agents
Conflict of interest statement
Conflicts of Interest: The authors have no conflicts of interest to declare.
References
- Gastroenterology. 2015 Sep;149(3):660-8.e1 - PubMed
- Hepatol Int. 2018 Feb;12(Suppl 1):91-101 - PubMed
- BMJ. 2009 Jul 21;339:b2700 - PubMed
- Gastroenterology. 2018 May;154(7):1964-1969 - PubMed
- Am J Gastroenterol. 1999 Apr;94(4):1077-82 - PubMed
- Hepatology. 2007 Sep;46(3):922-38 - PubMed
- J Ayub Med Coll Abbottabad. 2005 Jan-Mar;17(1):10-4 - PubMed
- Gastroenterology. 2014 Feb;146(2):412-19.e3 - PubMed
- Hepatology. 1992 Jun;15(6):1023-30 - PubMed
- Hepatol Int. 2018 Feb;12(Suppl 1):1-10 - PubMed
- Stat Med. 2010 Mar 30;29(7-8):932-44 - PubMed
- N Engl J Med. 2010 Mar 4;362(9):823-32 - PubMed
- J Hepatol. 1994 Feb;20(2):206-12 - PubMed
- Am J Gastroenterol. 2012 Dec;107(12):1872-8 - PubMed
- J Hepatol. 2015 Sep;63(3):743-52 - PubMed
- Am J Gastroenterol. 2000 Mar;95(3):768-71 - PubMed
- Scand J Gastroenterol. 1990 Jun;25(6):622-30 - PubMed
- Aliment Pharmacol Ther. 2007 Dec;26(11-12):1479-87 - PubMed
- Control Clin Trials. 1986 Sep;7(3):177-88 - PubMed
- J Hepatol. 2002 Apr;36(4):507-12 - PubMed
- J Hepatol. 1992 May;15(1-2):256-61 - PubMed
- Med Decis Making. 2013 Jul;33(5):641-56 - PubMed
- Expert Opin Drug Saf. 2009 Nov;8(6):755-68 - PubMed
- Am J Gastroenterol. 2009 Mar;104(3):617-23 - PubMed
- Res Synth Methods. 2013 Dec;4(4):291-323 - PubMed
- Lancet. 1997 Nov 22;350(9090):1495-9 - PubMed
- Gut. 2019 May;68(5):844-853 - PubMed
- Gastroenterology. 2015 Sep;149(3):528-31 - PubMed
- J Hepatol. 2002 Feb;36(2):163-8 - PubMed
- Lancet. 1982 Jul 10;2(8289):66-8 - PubMed
- Hepatology. 2020 Feb;71(2):600-610 - PubMed
- Korean J Intern Med. 2003 Sep;18(3):161-6 - PubMed
- Hepatology. 2002 Mar;35(3):609-15 - PubMed
- Clin Investig. 1994 Sep;72(9):653-9 - PubMed
- Hepatol Int. 2018 Feb;12(Suppl 1):81-90 - PubMed
- Hepatology. 1986 Jan-Feb;6(1):112-5 - PubMed
- J Clin Epidemiol. 2011 Feb;64(2):163-71 - PubMed
- Hepatology. 1997 May;25(5):1101-4 - PubMed
- BMJ. 1997 Sep 13;315(7109):629-34 - PubMed
- J Clin Exp Hepatol. 2015 Sep;5(3):204-12 - PubMed
- Aliment Pharmacol Ther. 2012 Apr;35(8):904-12 - PubMed
- J Hepatol. 1992 Nov;16(3):320-5 - PubMed
- N Engl J Med. 1996 Jan 25;334(4):246-54 - PubMed
- Hepatology. 2014 Sep;60(3):954-63 - PubMed
- J Hepatol. 2005 Jul;43(1):167-76 - PubMed
- Hepatol Int. 2018 Feb;12(Suppl 1):68-80 - PubMed
- J Hepatol. 2006 Oct;45(4):560-7 - PubMed
- BMJ. 2011 Oct 18;343:d5928 - PubMed
- N Engl J Med. 1995 Aug 31;333(9):555-60 - PubMed
- BMJ. 2003 Sep 6;327(7414):557-60 - PubMed
- Gastroenterology. 2001 Mar;120(4):975-83 - PubMed
Publication Types